Cardiovascular Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Student Research Committee, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
BMC Cardiovasc Disord. 2024 Sep 27;24(1):522. doi: 10.1186/s12872-024-04198-y.
Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram. The objective of this study was determined and compared left ventricle (LV)strain in patients with CSFP before and after receiving a high-dose atorvastatin.
This cross-sectional study was conducted on 51 patients with CSFP from the beginning of 2021 to the end of September 2022. Trans-thoracic Echocardiogram (TTE) was performed by an echocardiography specialist. Thereafter, the patient's basic information was entered into the researcher's checklist after treatment with atorvastatin 40 mg daily for eight consecutive weeks. After eight weeks, the patients were subjected again to TTE. The data were analyzed in SPSS statistical software.
The mean LV-GLS before taking atorvastatin was - 16.53%±3.63%. The mean LV-GLS after taking atorvastatin was 17.57%±3.53% (P.value = 0.01). The mean LV function before taking atorvastatin was 48.82%±9.19%. Meanwhile, the mean LV function after taking atorvastatin was 50.59%±7.91% (P = 0.01). There was no significantly change in left atrium volume (49.88 ± 0.68 vs. 49.9 + 0.67) after 8 weeks taking atorvastatin (P = 0.884).
The plasma ET-1 levels are elevated in CSFP patients, and atorvastatin improves coronary flow and endothelial function. As evidenced by the results of this study, the daily intake of 40 mg of oral atorvastatin during eight consecutive weeks in patients with CSFP significantly improved LV strain and LV function, however atorvastatin does not have a significant effect on improving the right ventricular function and pulmonary artery systolic pressure.
冠状动脉慢血流现象（CSFP）是一种公认的临床实体，其特征是在正常冠状动脉造影的情况下，冠状动脉显影延迟。本研究的目的是确定并比较 CSFP 患者在接受高剂量阿托伐他汀治疗前后的左心室（LV）应变。
这项横断面研究于 2021 年初至 2022 年 9 月底对 51 例 CSFP 患者进行。由心脏病专家进行经胸超声心动图（TTE）检查。此后，在连续 8 周每天服用阿托伐他汀 40mg 治疗后，将患者的基本信息输入研究者检查表中。8 周后，再次对患者进行 TTE。数据在 SPSS 统计软件中进行分析。
服用阿托伐他汀前的平均 LV-GLS 为-16.53%±3.63%。服用阿托伐他汀后的平均 LV-GLS 为 17.57%±3.53%（P 值=0.01）。服用阿托伐他汀前的平均 LV 功能为 48.82%±9.19%。而服用阿托伐他汀后的平均 LV 功能为 50.59%±7.91%（P=0.01）。服用阿托伐他汀 8 周后，左心房容积（49.88±0.68 与 49.9+0.67）无明显变化（P=0.884）。
CSFP 患者的血浆 ET-1 水平升高，阿托伐他汀可改善冠状动脉血流和内皮功能。本研究结果表明，CSFP 患者连续 8 周每天口服 40mg 阿托伐他汀可显著改善 LV 应变和 LV 功能，但阿托伐他汀对改善右心室功能和肺动脉收缩压无显著影响。
